Article source：
Sep 04,2026
View：
601 Recently, Kexing Biopharm and Visum Pharmaceutical Co., Ltd. (“visumpharma”) officially signed a commercialization cooperation agreement for Metoprolol Succinate Extended-Release Tablets in the Hong Kong market of China. Under the agreement, Kexing Biopharm will be responsible for the product’s registration application and commercial promotion in Hong Kong, China.
Metoprolol Succinate Extended-Release Tablets are a representative selective β1-adrenergic receptor blocker (β1-blocker). The product is primarily indicated for the treatment of hypertension, angina pectoris, and stable chronic heart failure accompanied by left ventricular systolic dysfunction. It is a well-established and classic cardiovascular medicine with widespread use globally.
Founded in June 2010 and headquartered in the Haikou National High-Tech Industrial Development Zone, Visumpharma is an integrated pharmaceutical company specializing in the R&D, manufacturing, export, and sales of high-end oral solid dosage forms. Its production lines have passed multiple U.S. FDA GMP inspections, and several of its products have been approved for marketing in China and the United States.
According to Visumpharma’s publicly available information, its Metoprolol Succinate Extended-Release Tablets (extended-release pellet technology) received the Drug Registration and Manufacturing Approval from China’s National Medical Products Administration (NMPA) in July 2021. Previously, the product had received approval from the U.S. Food and Drug Administration (FDA) in December 2018. In 2024, it ranked fourth in the U.S. market with a 4.03% market share.
The product’s quality and process stability have been continuously validated through long-term commercial supply in both domestic and international markets. For the Hong Kong market of China, the product’s approvals by both the NMPA and the FDA provide strong support for its subsequent registration application in Hong Kong and establish a solid foundation for its future commercialization.
In recent years, Kexing Biopharm has continued to expand its presence in the Guangdong-Hong Kong-Macao Greater Bay Area. The company’s proprietary product, Kehuang Capsules, has been approved for marketing in Hong Kong, China. In Macao, China, several in-licensed products, including Denosumab Injection, Aflibercept Intraocular Injection, and Nintedanib Esylate Soft Capsules, have also been approved for marketing. Its business now covers multiple therapeutic areas, including oncology, autoimmune diseases, antiviral therapies, and ophthalmology.
The commercialization partnership for Metoprolol Succinate Extended-Release Tablets with Visumpharma will further expand Kexing Biopharm’s cardiovascular product portfolio in the Hong Kong market of China.
Looking ahead, Kexing Biopharm will continue to work with more outstanding pharmaceutical companies in China to accelerate the global availability of high-quality medicines and serve more patients worldwide.
BACK TO LIST
Aug 11,2026
